Narrative review synthesizing the molecular mechanisms by which cytokines drive cartilage matrix degradation in OA. Asks: how do specific cytokines disrupt the balance between chondrocyte anabolic and catabolic activity, and what framework can guide therapeutic targeting?
When evaluating OA pathophysiology or counseling patients on disease-modifying strategies, recognize that OA involves active cytokine-driven molecular dysregulation — not passive wear — which is why intra-articular anti-inflammatory approaches (including IL-1 blockade) have biological rationale.
The IL-1/TNF-α synergism and the downstream NO pathway explain why inflammation, even at subclinical levels, can accelerate cartilage loss disproportionately to mechanical load alone.
Narrative review synthesizing the molecular mechanisms by which cytokines drive cartilage matrix degradation in OA. Asks: how do specific cytokines disrupt the balance between chondrocyte anabolic and catabolic activity, and what framework can guide therapeutic targeting?
When evaluating OA pathophysiology or counseling patients on disease-modifying strategies, recognize that OA involves active cytokine-driven molecular dysregulation — not passive wear — which is why intra-articular anti-inflammatory approaches (including IL-1 blockade) have biological rationale.
The IL-1/TNF-α synergism and the downstream NO pathway explain why inflammation, even at subclinical levels, can accelerate cartilage loss disproportionately to mechanical load alone.